Safety of antimalarials in the first trimester: An adaptive platform trial (SAFIRE)

Malaria in pregnancy can have devastating consequences, particularly in early pregnancy. Effective treatment in the first trimester can significantly improve maternal and pregnancy outcomes. However, first-trimester pregnancies are generally excluded from clinical trials resulting in new and effective antimalarials being withheld from use in early pregnancy. WHO updated its guidelines in 2022 from quinine to artemether-lumefantrine (AL) as the first-line treatment for uncomplicated malaria in the first trimester. However, there are insufficient data on the benefit-harm of other widely used artemisinin-based combination therapies. The trial will provide critical information on the safety and efficacy of alternatives to AL for treatment in the first trimester, benefiting settings where AL is not used and aligning with WHO’s strategy of multiple first-line therapies against antimalarial drug resistance. Results will be translated into policy and guidelines and ultimately ensure that healthcare providers and pregnant women have access to optimal treatment options for malaria in early pregnancy.

1. Phase IIIb, non-inferiority, Bayesian adaptive randomised platform trial comparing pyronaridine-artesunate (PA) and AL in Burkina Faso, Kenya and Mali. Primary outcome: Safety. Secondary outcomes: efficacy and tolerability.
2. Formative research to inform innovative trial recruitment and retention strategies,
3. Acceptability and feasibility to assess values and preferences of antimalarials during early pregnancy,
4. Implementation research to explore factors affecting implementation of AL in the first trimester to inform translation strategies, and
5. Cost-effectiveness of PA vs AL.

Project details

Drug-based Strategies
Vulnerable Populations

Jun 2024 — Nov 2028

$5.61M

Burkina Faso
Dem. Rep. of Congo
Kenya
Mali
Switzerland
The Netherlands
Uganda
United Kingdom